- Home
- INZY vs ESSA Comparison
INZY vs ESSA Comparison
Compare INZY & ESSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- ESSA
- Stock Information
- Founded
- INZY 2015
- ESSA 1916
- Country
- INZY United States
- ESSA United States
- Employees
- INZY N/A
- ESSA N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- ESSA Banks
- Sector
- INZY Health Care
- ESSA Finance
- Exchange
- INZY Nasdaq
- ESSA Nasdaq
- Market Cap
- INZY 188.2M
- ESSA 195.3M
- IPO Year
- INZY 2020
- ESSA N/A
- Fundamental
- Price
- INZY $1.28
- ESSA $20.50
- Analyst Decision
- INZY Strong Buy
- ESSA
- Analyst Count
- INZY 8
- ESSA 0
- Target Price
- INZY $17.75
- ESSA N/A
- AVG Volume (30 Days)
- INZY 829.2K
- ESSA 37.2K
- Earning Date
- INZY 03-11-2025
- ESSA 01-27-2025
- Dividend Yield
- INZY N/A
- ESSA 2.94%
- EPS Growth
- INZY N/A
- ESSA N/A
- EPS
- INZY N/A
- ESSA 1.78
- Revenue
- INZY N/A
- ESSA $67,843,000.00
- Revenue This Year
- INZY N/A
- ESSA N/A
- Revenue Next Year
- INZY N/A
- ESSA N/A
- P/E Ratio
- INZY N/A
- ESSA $11.57
- Revenue Growth
- INZY N/A
- ESSA N/A
- 52 Week Low
- INZY $1.29
- ESSA $15.29
- 52 Week High
- INZY $7.80
- ESSA $21.50
- Technical
- Relative Strength Index (RSI)
- INZY 19.19
- ESSA 62.93
- Support Level
- INZY $1.32
- ESSA $19.35
- Resistance Level
- INZY $1.44
- ESSA $20.67
- Average True Range (ATR)
- INZY 0.25
- ESSA 0.53
- MACD
- INZY -0.10
- ESSA 0.19
- Stochastic Oscillator
- INZY 1.54
- ESSA 96.09
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About ESSA ESSA Bancorp Inc.
ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.